G-protein coupled receptors bivalent ligands and drug design

Bibliography

• PINDER RM, BROGDEN RN, SPEIGHT TM, AVERY GS: Hexoprenaline : a review of its pharmacological prop-erties and therapeutic efficacy with particular refer-ence to asthma. Drugs (1977) 14:1–28.
   PubMed Web of Science ®Google Scholar
• TURNHEIM K, KRAUPP O: Pulmonary and systemic cir-culatory effects and p-adrenergic selectivity of hexo-prenaline, salbutamol, oxyfedrine, and isoproterenol. Eur. j Pharmacol. (1971) 15:231–239.
   PubMedGoogle Scholar
• HOWE R, RAO BS, CHODNEKAR MS: 6-Adrenergic block-ing agents. VII. 2-(1,4-Benzodioxanyll) and 2-chromanyl analogs of pronethalol [2-isopropylamino-1(2-naphthyDethanol]. J. Med. Chem. (1970) 13:169–176.
   Google Scholar
• VAN DE WATER A, JANSSENS W, VAN NEUTEN J et al:Pharmacological and hemodynamic profile of nebivo-lol, a chemically novel, potent, and selective 61-adrenergic antagonist. J. Cardiovasc. Pharmacol. (1988) 11:552–563.
   PubMedGoogle Scholar
• PAUWELS PJ, GOMMEREN W, VAN LOMMEN G, JANSSEN PAJ, LEYSEN JE: The receptor binding profile of the new antihypertensive agent nebivolol and its stereoiso-mers compared with various p-adrenergic blockers. Mot. Pharmacol. (1988) 34:843–851.
   PubMed Web of Science ®Google Scholar
• VAN LOMMEN G, DE BRUYN M, SCHROVEN M: Synthesis and pharmacological properties of nebivolol, a new antihypertensive compound. J. Pharm. Belg., (1990) 45:355–360.
   PubMedGoogle Scholar
• PAUWELS PJ, VAN GOMPEL P, LEYSEN JE: Human 61-and i32-adrenergic receptor binding and mediated accumu-lation of cAMP in transfected Chinese hamster ovary cells - profile of nebivolol and known p-adrenergic blockers. Biochem. Pharmacol (1991) 42:1683–1689.
   PubMedGoogle Scholar
• KIZUKA H, HANSON RN: 13-Adrenoceptor antagonist ac-tivity of bivalent ligands. 1. Diamide analogues of prac-tolol. J. Med. Chem. (1987) 30:722–726.
   Google Scholar
• KIERSTEAD R.W, FARAONE A, MENNONA F et al.: 131 se-lective adrenoceptor antagonists. 1. synthesis and 13-a-drenergic blocking activity of a series of binary (aryloxy) propanolamines. J. Med. Chem. (1983) 26:1561–1569.
   Google Scholar
• •This paper clearly demonstrates the importance of linker points of attachment for the receptor-subtypes selectivity of bivalent ligands.
   Google Scholar
• PITHA J, MILECKI J, CZAJKOWSKA T, KUSIAK JW: 13-Adre-nergic antagonists with multiple pharmacophores: persistent blockade of receptors. J. Med. Chem. (1983) 26:7–11.
   PubMed Web of Science ®Google Scholar
• BARLOW RB, SHEPHERD MK: A further search for selec-tive antagonist at M2-muscarinic receptors. Br. J. Phar-macol. (1986) 89:837–843.
   PubMedGoogle Scholar
• MELCHIORRE C, ANGELI P, LAMBRECHT G, MUTSCHLERE, PICCHIO MT, WESS J: Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with at-ropine and gallamine. Eur. J. Pharmacol (1987) 144:117–124.
   PubMedGoogle Scholar
• MELCHIORRE C, MINARINI A, ANGELI P, GIARDINA D, GULINI U, QUAGLIA W: Polymethylene tetraamines as muscarinic receptor probes. Trends Pharmacol. Sci. (1989) 12:55–59.
   Google Scholar
• ••Comprehensive SAR study of M2 bivalent ligands followedby an interesting binding hypothesis.
   Google Scholar
• PIERGENTILI A, QUAGLIA W, TAYEBATI KS, PAPARELLI F,MALMUSI L, BRASILI L: Synthesis and muscarinic recep-tors affinity of a series of antagonist bivalent ligands. IL Farmaco (1994) 49:83–87.
   PubMedGoogle Scholar
• MOSER U, GUBITZ C, GALVAN M, IMMEL-SEHR A, LAM-BRECHT G, MUTSCHLER E: Aliphatic and heterocyclic analogues of arecaidine propargyl ester. Structure-activity relationships of mono-and bivalent ligands at muscarinic M1 (M4), M2 and M3 receptor subtypes. Arzneim.-Forsch/Drug Res. (1995) 45(1)450–455.
   Google Scholar
• PORTOGHESE PS: Bivalent ligands and the message - address concept in the design of selective opioid re-ceptor antagonists. Trends Pharmacol Sci. (1989) 10:230–235.
   PubMedGoogle Scholar
• ••A key review on concepts and examples of bivalent ligandsin the opioid field.
   Google Scholar
• PORTOGHESE PS: The role of concepts in structure-activity relationship studies of opioid ligands. J. Med. Chem. (1992) 35:1927–1937.
   PubMedGoogle Scholar
• PORTOGHESE PS, LARSON DL, YIM CB et al.:Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J. Med. Chem. (1985) 28:1140–1141.
   PubMed Web of Science ®Google Scholar
• TAKEMORI AE, YIM CB, LARSON DL, PORTOGHESE PS:Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice. Eur. J. Pharma-col. (1990) 186:285–288.
   PubMedGoogle Scholar
• EREZ E, TAKEMORI AE, PORTOGHESE PS: Narcotic an-tagonistic potency of bivalent ligands which contain p-Naltrexamine. Evidence for bridging between proxi-mal recognition sites. J. Med. Chem. (1982) 25:847–849.
   Google Scholar
• CHIA-EN UN, TAKEMORI AE, PORTOGHESE PE: Synthe-sis and x-opioid antagonist selectivity of a norbinaltor-phimine congener. Identification of the address moiety required for x-antagonist activity. J. Med. Chem. (1993) 36:2412–2415.
   Google Scholar
• PORTOGHESE PS, UN CE, FAROUZ-GRANT F, TAKEMORIAE: Structure-activity relationship of N17'-substituted norbinaltorphimine congeners. Role of the N17' basic group in the interaction with a putative address sub-site on the x opioid receptor. J. Med. Chem. (1994) 37:1495–1500.
   Google Scholar
• SHIMOHIGASHI Y, COSTA T, CHEN H C, RODBARD D: Di- meric tetrapeptide enkephalins display extraordinary selectivity for .5 opiate receptor. Nature (1982) 297:333–335.
   Google Scholar
• ••One of the very first papers demonstrating superior bindingselectivity upon ligand dimerisation.
   Google Scholar
• SHIMOHIGASHI Y, COSTA T, MATSUURA S, CHEN HC, RODBARD D: Dimeric enkephalins display enhanced affinity and selectivity for the delta opiate receptor. Mol Pharmacol. (1982) 21:558–563.
   PubMedGoogle Scholar
• COSTA T, SHIMOHIGASHI Y, KRUMINS SA, MUNSON PJ,RODBARD D: Dimeric pentapeptide enkephalin: a novel probe of delta opiate receptors. Life Sci. (1982) 31:1625–1632.
   PubMedGoogle Scholar
• LUTZ RA, CRUCIANI RA, SHIMOHIGASHI Y et al.: In-creased affinity and selectivity of enkephalin tripep-tide (Tyr-u-Ala-Gly) dimers. Eur. J. Pharmacol. (1985) 111:257–261.
   PubMedGoogle Scholar
• COSTA T, WeRSTER M, HERZ A, SHIMOHIGASHI Y, CHENH-C, RODBARD D: Receptor binding and biological ac-tivity of bivalent enkephalins. Biochem. Pharmacol. (1985) 34(1):25–30.
   PubMedGoogle Scholar
• SCHMAUSS, C SHIMOHIGASHI Y, JENSEN T, RODBARB D,YAKSH TL: Studies on spinal opiate receptor pharma-cology. III. Analgetic effects of enkephalin dimers as measured by cutaneous-thermal and visceral-chemical responses. Brain Res. (1985) 337:209–215.
   Google Scholar
• LUTZ RA, COSTA T, CRUCIANI RA et al: Increased affin-ity of dimeric enkephalins is not dependent on recep-tor density. Neuropeptides (1985) 6:167–174.
   PubMedGoogle Scholar
• SHIMOHIGASHI Y, OGASAWARA T, KOSHIZAKA T et al.:Interaction of dimers of inactive enkephalin frag-ments with µ opiate receptors. Biochem. Biophy. Res. Comm. (1987) 146:1109–1115.
   PubMedGoogle Scholar
• FISHER LE, ROSENKRANZ RP, CLARK RD et al.:N,N-6-bis-(3,4.dihydroxybenzy0 pyrrolidinyl hexane, a potent, selective, orally active dopamine analog with hypotensive and diuretic activity. Bioorg. Med. Chem. Lett. (1995) 5:2371–2376.
   Google Scholar
• GOODING OW, BANSAL RP: Enantioselective synthesisof 2-substituted pyrrolidines from 4-hydroxynitriles. Application to the synthesis of the dopamine agonist RS-59022. Syn. Comm. (1995) 25:1155–1166.
   Google Scholar
• WRIGHT J, DOWNING D, EFFNER T, PUGSLEY T, MACK-ENZIE R, WISE L: Discovery of selective dopamine D3 ligands: I. dimeric 244-(3-aminopropoxy) phenyl] benzimidazole antagonists. Bioorg. Med. Chem. Lett. (1995) 5:2541–2546.
   Google Scholar
• CORBIN A.E, PUGSLEY TA, AKUNNE HC et al.: Pharma-cological characterization of PD 152255, a novel di-meric benzimidazole dopamine D3 antagonist. Pharmacol. Biochem. Behav. (1998) 59: 487–493.
   Google Scholar
• LEBOULLUEC KL, MATTSON RJ, MAHLE CD, MCGOVERNRT, NOWAK HP, GENTILE AJ: Bivalent indoles exhibit-ing serotonergic binding affinity. Bioorg. Med. Chem. Lett. (1995) 5:123–126.
   Google Scholar
• HALAZY S, PEREZ M, FOURRIER C et al: serotonindimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT1B/1n ago-nists. J. Med. Chem. (1996) 39:4920–4927.
   PubMedGoogle Scholar
• •This study shows that improvement in binding affinity/se-lectivity with 5-HT dimers is not spacer-dependent.
   Google Scholar
• PEREZ M, PAUWELS P, FOURRIER JC et al.: Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1a agonist. Bioorg. Med. Chem. Lett. (1998) 8:675–680.
   PubMedGoogle Scholar
• ••Example of improvement of in vivo properties upon drugdimerisation.
   Google Scholar
• PEREZ M, JORAND-LEBRUN C, PAUWELS PJ, PALLARD I,HALAZY S: Dimers of 5-HT1 ligands preferentially bind to 5-HT1B/1n receptor subtypes. Bioorg. Med. Chem. Let-ters (1998) 8:1407–1412.
   PubMedGoogle Scholar
• PAUWELS PJ, DUPUIS DS, PEREZ M, HALAZY S: Dimeriza-tion of 8-011-DPAT increases activity at serotonin 5-HT1A receptors. Naunyn-Schmiedeberg's Arch Pharma-col. (1998) 358:404–410.
   PubMedGoogle Scholar
• ••Study suggesting that a dimeric ligand can activate a recep-tor through a different binding mode.
   Google Scholar
• MOLTZEN EK, PERREGAARD J, MEIER E: Ligands withsubnanomolar affinity and preference for the cs2 bind-ing site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. J. Med. Chem. (1995) 38:2009–2017.
   Google Scholar
• PENKE B, SZCJCS M: Effect of gastrin analogues on thegastrin receptor of the stomach. In: Aminergic and Pep-tidergic Receptors. ES Vizi, M Wollemann (Eds.), (1979) 14:205–214.
   Google Scholar
• CHERONIS JC, WHALLEY ET, NGUYEN KT et al.: A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem. (1992) 35:1563–1572.
   PubMed Web of Science ®Google Scholar
• ••Remarkable study on the importance of spacer length andpoints of attachment of bivalent ligands.
   Google Scholar
• CHERONIS JC, WHALLEY ET, ALLEN LG et al: Design, syn-thesis, and in vitro activity of bis(succinimido) hexane peptide heterodimers with combined B1 and B2 an-tagonist activity. J. Med. Chem. (1994) 37:348–355.
   PubMedGoogle Scholar
• VEVREK RJ, STEWART J M: Succinyl bis-bradykinins: Po-tent agonists with exceptional resistance to enzymatic degradation. In: Peptides: Proceedings of the Eighth Ameri-can Peptide Symposium. Hurby VJ, Rich DH (Eds.), Pierce Chemical Co., Rockford, IL, USA (1983):381–384.
   Google Scholar
• KODAMA H, SHIMOHIGASHI Y, SAKAGUCHI K et al.: Di-merization of neurokinin A and B COOH-terminal hep-tap eptide fragments enhanced the selectivity for tachykinin receptor subtypes. Eur. J. Pharmacol (1988) 151:317–320.
   PubMedGoogle Scholar
• HIGUCHI Y, TAKANO Y, SHIMAZAKI H et al.: Dimericsubstance P analogue shows a highly potent activity of the vivo salivary secretion in the rat. Eur. J. Pharmacol (1989) 160:413–416.
   PubMedGoogle Scholar
• •First example of improvement of in vivo properties of an agonist upon dimerisation.
   Google Scholar
• SAKAGUCHI K, SHIMOGASHI Y, MATSUMOTO H et al.: Characteristic in vitro and in vivo activities of tachyki-nin peptide dimers. Peptide Chem. (1988) 57–60.
   Google Scholar
• SCHOLS D, STRUYF S, DAMME J V, ESTE J A, HENSON G, DE CLERCQ E: Inhibition of T-tropic HIV strains by se-lective antagonization of the chemokine receptor CXCR4. J. Exp. Med. (1997) 186:1383–1388.
   PubMed Web of Science ®Google Scholar
• BALASUBRAMANIAM A, ZHAI W, SHERIFF S et al.: Bis(31/311 ([Cys31,Trp32, Nva34] NPY-(31-36)): a spe-cific NPY Y-1 receptor antagonist. J. Med. Chem. (1996) 39:811–813.
   PubMedGoogle Scholar
• UEGAKI K, MURASE S, NEMOTO N, KOBAYASHI Y, YOSHIKAWA S, YUMOTO N: Effects of covalent dimeri-zation on the structure and function of the carboxy-terminal fragment of neuropeptide Y. Biochem. Bio-phys. Res. Comm. (1997) 241:737–743.
   PubMedGoogle Scholar
• DANIELS AJ, MATTHEWS JE, SLEPETIS RJ et al.: High-affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. USA (1995) 92:9067–9071.
   PubMed Web of Science ®Google Scholar
• FAUCHERE J-L, ROSSIER M, CAPPONI A, VALLOTTON M, B: Potentiation of the antagonistic effect of ACTH11-24 on steroidogenesis by synthetic of covalent dimeric conjugates. FEBS Lett. (1985) 183:283–286.
   PubMedGoogle Scholar
• CAPORALE LH, CHOREV M, LEVY JJ et al: Characteriza-tion of parathyroid hormone antagonists. Peptides: Pro-ceedings of the 10th American Peptide Symposium. Marshall GR (Ed.), Pierce Chem. Co., Rockford, USA (1988):449–451.
   Google Scholar
• CARRITHERS MD, LERNER MR: Synthesis and characteri-zation of bivalent peptide ligands targeted to G-protein-coupled receptors. Chem. Biol. (1996) 3:537–542.
   PubMedGoogle Scholar
• CONN PM, ROGERS DC, STEWART JM, NIEDEL J, SHEF-FIELD T: Conversion of a gonadotropin-releasing hor-mone antagonist to an agonist. Nature (1982) 296:653–655.
   PubMedGoogle Scholar
• •First example of inversion of intrinsic activity upon ligand dimerisation.
   Google Scholar
• CONN PM, ROGERS DC, MCNEIL R: Potency enhance-ment of a GnRH agonist: GnRH-receptor microaggre-gation stimulates gonadotropin release. Endocrinology (1982) 111:335–337.
   PubMedGoogle Scholar
• FENIUK W, HUMPHREY PPA: The development of a highly selective 5-HT1 receptor agonist, sumatriptan, for the treatment of migraine. Drug Dev. Res. (1992) 26:235–240.
   Google Scholar
• HALAZY S, LAMOTHE M, JORAND-LEBRUN C: 5-Hr1st10antagonists and depression. Exp. Opin. Ther. Patents (1997) 7 (4):339–352.
   Web of Science ®Google Scholar
• BAGGIOLINI M, DEWALD B, MOSER B: Human chemoki-nes: an update. Ann. Rev. Immunol (1997) 15:675–705.
   PubMed Web of Science ®Google Scholar
• RAJARATHNAM K, SYKES BD, KAY CM et al.: Neutrophil activation by monomeric interleukin-8. Science (1994) 264:90–92.
   PubMed Web of Science ®Google Scholar
• BURROWS SD, DOYLE ML, MURPHY KP et al: Determina-tion of the monomer-dimer equilibrium of interleukin-8 reveals it is a monomer at physiological concentrations. Biochemistry (1994) 33:12741–12745.
   PubMedGoogle Scholar
• ZHANG Y, ROLLINS BJ: A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol. Cell. Biol. (1995) 15:4851–4855.
   PubMedGoogle Scholar
• LAURENCE JS, HWANG AC, LIWANG PJ: Effect of N-Terminal truncation and solution conditions on che-mokine dimer stability: nuclear magnetic resonance structural analysis of macrophage inflammatory pro-tein 113 mutants. Biochemistry (1998) 37:9346–9354.
   PubMedGoogle Scholar
• ESTE JA, CABRERA C, DE CLERCQ E et al: Activity of dif-ferent bicyclam derivatives against human immuno-deficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol. Pharmacol. (1999) 55:67–73.
   PubMed Web of Science ®Google Scholar
• HERBERT TE, MOFFETT S, MORELLO J-P et al.: A peptide derived from a p2-adrenergic receptor transmem-brane domain inhibits both receptor dimerization and activation. J. Biol. Chem. (1996) 271:16384–16392.
   PubMed Web of Science ®Google Scholar
• CVEJIC S, DEVI LA: Dimerization of the .5 opioid recep-tor: implication for a role in receptor internalization. J. Biol. Chem. (1997) 272:26959–26964.
   Google Scholar
• NIMCHINSKY EA, HOF PR, JANSSEN WGM, MORRISON JH, SCHMAUSS C: Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J. Biol. Chem. (1997) 272:29229–29237.
   PubMed Web of Science ®Google Scholar
• MAGGIO R, VOGEL Z, WESS J: Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular 'cross-talk' between G-protein-linked receptors. Proc. Natl. Acad. Sci. USA (1993) 90:3103–3107.
   PubMed Web of Science ®Google Scholar
• ••Elegant demonstration of cross-talk between GPCR.
   Google Scholar
• MONNOT C, BIHOREAU C, CONCHON S, CURNOW K M, CORVOL P, CLAUSER E: Polar residues in the transmem-brane domains of the Type 1 angiotensin II receptor are required for binding and coupling. J. Biol. Chem. (1996) 271:1507–1513.
   PubMed Web of Science ®Google Scholar